Oxaliplatin

Generic Name: Oxaliplatin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₂O_₄Pt

CAS Number: 61825-94-3

Unique Ingredient Identifier: 04ZR38536J

Background: Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication: Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions: Advanced Colorectal Cancer, Stage III Colon Cancer

Associated Therapies: -

Clinical Trials

Oxaliplatin in Treating Children With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-23

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 26

Registration Number: NCT00005844

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 119

Registration Number: NCT00043004

Locations: 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇭🇺
National Institute of Oncology, Budapest, Hungary
🇬🇧
Churchill Hospital, Oxford, England, United Kingdom

and more 40 locations

Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Terminated

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: oxaliplatin
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 59

Registration Number: NCT00005856

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma

Interventions: Drug: oxaliplatin

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00006473

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00008294

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

Phase 1

Completed

Conditions: Adenocarcinoma of the Rectum
Stage II Rectal Cancer
Stage III Rectal Cancer

Interventions: Drug: oxaliplatin
Drug: fluorouracil
Radiation: external beam radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00006094

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Liver Metastases
Stage IV Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: floxuridine
Drug: dexamethasone
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00026234

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: ZD1839
Drug: oxaliplatin

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 14

Registration Number: NCT00026299

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 9 locations